Ent001
Type 1 Diabetes & Inflammatory Bowel Disease (Ulcerative Colitis)
Phase 1Active
Key Facts
Indication
Type 1 Diabetes & Inflammatory Bowel Disease (Ulcerative Colitis)
Phase
Phase 1
Status
Active
Company
About Enthera Pharmaceuticals
Enthera Pharmaceuticals is a private, clinical-stage biotech pioneering a novel therapeutic approach for autoimmune diseases by targeting the IGFBP3/TMEM219 apoptosis pathway. Its lead candidate, Ent001, is in Phase 1 development with the potential to modify disease progression in Type 1 Diabetes and Inflammatory Bowel Disease by protecting and restoring stem cells. Backed by notable life science investors like Sofinnova Partners and JDRF, the company is advancing a pipeline of monoclonal antibodies and fusion proteins derived from its proprietary discovery engine to address significant unmet medical needs.
View full company profile